EGFR (Epidermal growth factor receptor) overexpression has been detected in almost 1/3 of patients with highly aggressive inflammatory breast cancer (IBC) and in more than half of patients with triple-negative breast cancer (TNBC), which indicates a poor prognosis [11]. Here, EGFR is linked to triple-negative breast carcinoma.